MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Ventfort Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Ventfort is an orally administered Khavinson vascular peptide bioregulator (Cytomax complex A-3) derived from calf blood-vessel tissue. Rather than binding a receptor, short peptide bioregulators are proposed to enter the cell nucleus and interact with DNA promoter regions and histones, nudging tissue-specific gene expression toward a 'younger' pattern; in the vascular system the corresponding synthetic tripeptide KED (Vesugen) has been reported to normalize endothelin-1 and restore endothelial proliferation markers in cell culture (PMC8227791). The standard course is 20 mg/day (two 10 mg capsules with meals) for 30 days, repeated every 4-6 months. The subcutaneous vial-and-water protocol shown here is an educational measurement model only — Ventfort is taken orally, not injected. Human pharmacokinetics are not established, and clinical evidence comes mostly from a single research group's small studies. Ventfort is sold as a dietary supplement, not an approved drug, and nothing here is medical advice.
Reconstitute: Add 2.5 mL bacteriostatic water → 40 mg/mL concentration.
Typical dose: 20 mg/day (2 × 10 mg capsules) for a 30-day course
Easy measuring: At 40 mg/mL, 1 unit = 0.01 mL = 0.4 mg (400 mcg) on a U-100 insulin syringe.
Storage: Capsules: store at room temperature, dry and protected from direct light. Educational reconstitution model: lyophilized research powder kept frozen at −20 °C; once reconstituted with bacteriostatic water, refrigerate at 2-8 °C and use within ~4 weeks.
Half-life: Not established in humans; free di-/tripeptides are hydrolyzed within minutes. A manufacturer claim of 4-6 months' duration of effect per 30-day course is unverified by pharmacokinetic data.
Route: Oral capsules (10 mg each) taken with meals; the subcutaneous reconstitution figures here are an educational measurement model only, not a real route.
Status: Not FDA- or EMA-approved. Sold as a dietary supplement for research/educational use; efficacy not independently confirmed in large trials.
About Ventfort
Ventfort is the vascular (blood-vessel) member of the Khavinson "Cytomax" line, a peptide bioregulator built around peptide complex A-3 isolated from calf vascular tissue and proposed to support endothelial renewal and vessel tone by epigenetically tuning gene expression in vascular cells [1][2]. Clinically, and in every real-world protocol, Ventfort is taken ORALLY as 10 mg capsules with food; the subcutaneous reconstitution figures below are an educational measurement reference only, not the actual route of administration.\n\nThis guide models a 100 mg vial reconstituted with 2.5 mL of bacteriostatic water (40 mg/mL) so the standard oral dose maps cleanly onto a U-100 insulin syringe: 10 mg ≈ 25 units, 20 mg ≈ 50 units, and 40 mg ≈ 100 units (a full syringe, which would be split). The established Ventfort dosage is 20 mg per day, two 10 mg capsules, for a 30-day course repeated every 4-6 months; lower-intensity use is 10 mg/day and the upper documented range is about 40 mg/day [3].\n\nFrequency: Once daily with meals for 30 days, then off until the next course. Note that the standard designation for this complex is A-3 (vascular); Ventfort is not FDA- or EMA-approved and is presented here for educational purposes only [6].
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.5 mL of bacteriostatic water into a sterile syringe.
Inject the water slowly down the inner glass wall of the 100 mg Ventfort vial; do not spray it directly onto the lyophilized powder, and avoid vigorous shaking.
Swirl gently until the solution is completely clear; this yields a 40 mg/mL concentration (400 mcg per insulin-syringe unit).
Store refrigerated at 2-8 °C and draw the prescribed units per dose: 10 mg ≈ 25 units, 20 mg ≈ 50 units, 40 mg ≈ 100 units (split across two injections).
Educational note: Ventfort is clinically taken ORALLY as capsules with meals, and capsule-grade tissue extract is neither sterile nor validated for injection — these subcutaneous reconstitution figures are a dose-measurement reference only, not a recommended delivery method.
Interactive Ventfort Syringe Calculator
Currently visualizing the 100 mg vial reconstituted with 2.5 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 100mg dry powder in 2.5mL water yields 40.00 mg/mL. To evaluate a 250mcg dose, pull to 0.6 units (1 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Lower-intensity / maintenance (1 × 10 mg) | 10000 mcg (10 mg) | 25 units (0.25 mL) |
| Standard 30-day course (2 × 10 mg/day) | 20000 mcg (20 mg) | 50 units (0.50 mL) |
| Upper documented range (up to 40 mg/day, split) | 40000 mcg (40 mg) | 100 units (1.00 mL) |
Administration guidelines: Refer to guidelines | 2.5 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 100 mg vial.
Peptide Vials (Ventfort, 100 mg each):
- check~12 vials for an 8-week continuous educational course at 20 mg/day (1120 mg total).
- check~17 vials for a 12-week course; ~23 vials for a 16-week course.
- checkReal-world reference: one 30-day oral course at 20 mg/day equals 600 mg, about 6 vials' worth (or 60 × 10 mg capsules).
- checkOrder a little extra to cover reconstitution waste and partial draws.
Insulin Syringes (U-100):
- checkOne injection per day in this model: ~60 syringes (about one box) for 8 weeks.
- check~90 syringes for 12 weeks; ~120 syringes for 16 weeks.
- check0.5 mL / 50-unit syringes are convenient since the standard 20 mg dose is 50 units.
- checkUse a new sterile syringe for every draw and never share needles.
Bacteriostatic Water (30 mL bottles): Use 2.5 mL per vial for reconstitution.
- check~30 mL (one 30 mL bottle) for an 8-week course (12 vials × 2.5 mL).
- check~43 mL (two bottles) for 12 weeks; ~58 mL (two bottles) for 16 weeks.
- checkEach 100 mg vial takes 2.5 mL to reach 40 mg/mL.
- checkRefrigerate reconstituted vials at 2-8 °C and use within ~4 weeks.
Alcohol Swabs:
- check~120 swabs for 8 weeks (about two per injection: vial stopper plus skin site).
- check~180 swabs for 12 weeks; ~240 swabs for 16 weeks.
- checkWipe the vial stopper and the injection site before each use.
- checkKeep a sharps container on hand for safe needle disposal.
Mechanism of Action (MOA)
Ventfort is a "Cytomax" peptide bioregulator: a tissue extract built around peptide complex A-3, a low-molecular-weight fraction isolated from the vascular (blood-vessel) tissue of young calves at the St. Petersburg Institute of Bioregulation and Gerontology. It belongs to the family of short-peptide bioregulators developed by Vladimir Khavinson, whose central hypothesis — the peptide theory of ageing — holds that organ-specific regulatory peptides act as information carriers that coordinate gene expression within their tissue of origin, and that their age-related decline drives structural and functional deterioration [3].\n\nThe proposed mechanism is epigenetic rather than receptor-based. According to Khavinson's systematic review, ultrashort peptides (2-7 amino acids) can pass through cell and nuclear membranes, enter the nucleus and nucleolus, and interact directly with histone proteins and single- and double-stranded DNA, recognizing specific nucleotide motifs in gene promoter regions and thereby raising or lowering transcription in a tissue-specific way [1]. For the vascular system, the best-characterized molecule expressing this activity is the synthetic tripeptide KED (Lys-Glu-Asp, marketed as Vesugen), which is explicitly described in the peer-reviewed literature as "a vasoprotective peptide derived from cattle vessels" — the same tissue source as Ventfort's A-3 complex [2]. In endothelial cell cultures from atherosclerotic and restenotic vessels, Khavinson-group reports describe KED normalizing expression of the vasoconstrictor endothelin-1, restoring the gap-junction protein connexin, and upregulating the proliferation marker Ki-67 (MKI67), changes interpreted as renewal of aged or damaged endothelium [1][2].\n\nPharmacokinetics are essentially uncharacterized in humans and are the weakest part of the evidence base. Ventfort is taken orally, and intact di- to tetrapeptides are rapidly hydrolyzed by gastrointestinal and plasma peptidases, so the circulating half-life of any absorbed free peptide is on the order of minutes and the oral bioavailability of an intact complex is unproven. Manufacturers claim that a single 30-day course produces effects lasting 4-6 months, but this is a marketing statement, not a measured pharmacokinetic or pharmacodynamic parameter; there is no validated Cmax, Tmax, or elimination half-life for Ventfort.\n\nThe subcutaneous reconstitution scheme on this page is an educational measurement convention used across this site; Ventfort's real-world route is oral capsules and no injectable form is clinically used. Clinical evidence comes almost entirely from one research group and from small, largely unblinded studies — for example, the synthetic vascular tripeptide improved penile arterial blood flow in men with atherosclerotic vasculogenic erectile dysfunction [5] — alongside rodent data suggesting peptide preparations can extend mean lifespan and reduce tumor incidence [4]. None of this has been independently replicated in large Western randomized trials, and Ventfort is sold as a dietary supplement, not an approved drug [6].
Clinical Trial Efficacy Highlights
- starKhavinson and colleagues' systematic review (Molecules, 2021) summarizes the mechanism proposed for Ventfort-class bioregulators: short peptides of 2-7 amino acids can penetrate cell and nuclear membranes, interact with histones and single- and double-stranded DNA, and recognize specific promoter motifs to up- or down-regulate transcription in a tissue-specific manner [1].
- starIn a peer-reviewed Alzheimer's-model study (Pharmaceuticals, 2021), the vascular tripeptide KED — explicitly described as 'a vasoprotective peptide derived from cattle vessels,' the same tissue source as Ventfort's A-3 complex — bound promoter regions of multiple stress-response and synaptic genes (e.g., CASP3, GAP43, SOD2, APOE) and preserved dendritic spines in 5xFAD mice, supporting the epigenetic, gene-regulatory model of action [2].
- starKhavinson-group reports describe the vascular tripeptide normalizing expression of the vasoconstrictor endothelin-1, restoring the gap-junction protein connexin, and increasing the proliferation marker Ki-67 (MKI67) in endothelial cultures from normal, atherosclerotic, and restenotic vessels, interpreted as renewal of aged or damaged endothelium [1][2].
- starA clinical study by Kitachev and colleagues (Advances in Gerontology, 2014) administered the synthetic vascular tripeptide (Vezugen) to 41 older men with vasculogenic erectile dysfunction secondary to atherosclerosis and reported significant improvement in penile main-artery blood flow by both clinical and objective measures; the trial was small, single-center, and not placebo-controlled [5].
- starAnisimov and Khavinson's review (Biogerontology, 2010) reports that long-term administration of peptide preparations increased mean lifespan by roughly 20-40% and suppressed spontaneous and induced tumor development in rodents, the basis for the 'geroprotector' framing of the Cytomax line — though these are animal data, not vascular endpoints in humans [4].
- starKhavinson's foundational monograph 'Peptides and Ageing' (Neuro Endocrinology Letters, 2002) sets out the peptide theory of ageing and the rationale for organ-specific bioregulators such as the vascular complex in Ventfort, but it is a narrative review and conceptual framework rather than controlled clinical evidence [3].
- starAcross the literature, the major limitation is that nearly all efficacy data originate from a single research group and from small, often unblinded studies; there are no large, independent, Western randomized controlled trials of Ventfort, and supplement-grade preparations are not standardized for peptide content [1][2].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningManufacturer and reseller materials report Ventfort to be well tolerated with no characteristic toxic or allergic effects in their own data; however, this safety claim comes from the producer rather than from independent pharmacovigilance, so the real adverse-effect profile is poorly defined [3].
- warningBecause it is an animal-tissue extract (calf vascular tissue), allergic or hypersensitivity reactions are possible, particularly in people with known sensitivity to bovine proteins.
- warningThe capsule excipients (lactose, beet sugar/sucrose, starch, microcrystalline cellulose) are relevant to people with lactose intolerance or those managing carbohydrate and sugar intake.
- warningHuman pharmacokinetics, long-term safety, drug interactions, and carcinogenicity have not been formally studied; theoretical concerns about stimulating cell proliferation (for example endothelial Ki-67/MKI67) in people with active cancer or proliferative vascular disease cannot be excluded.
- warningThere are no established safety data in pregnancy, breastfeeding, or in children, and these groups should avoid it.
- warningThe subcutaneous reconstitution model on this page is illustrative only — Ventfort is not formulated, sterilized, or validated for injection, and injecting a capsule-grade tissue extract could cause infection, local reactions, or immune responses.
- warningBovine-derived tissue extracts carry a theoretical (not documented for these specific products) concern about transmissible animal pathogens, and sourcing and processing quality vary between resellers.
- warningRegulatory/research status: Ventfort is NOT approved by the FDA or EMA as a drug, is not standardized or independently verified for potency, and is sold only as a dietary supplement; claimed vascular and anti-aging benefits are not confirmed by regulatory agencies [6].
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Ventfort dosage?expand_more
The established Ventfort dosage is 20 mg per day — two 10 mg capsules taken with meals — for a 30-day course, usually repeated every 4-6 months (or every 2-3 months for more intensive support). Some protocols use one to two capsules one or two times daily, giving a documented range of roughly 10-40 mg/day. These are supplement-label and Khavinson-clinic conventions, not doses validated by regulatory agencies.
How do you reconstitute Ventfort, and is it really injected?expand_more
In real use Ventfort is not injected — it is an oral capsule. The reconstitution protocol here is an educational measurement model only: a 100 mg vial mixed with 2.5 mL of bacteriostatic water gives 40 mg/mL (400 mcg per insulin-syringe unit), so 10 mg ≈ 25 units and 20 mg ≈ 50 units. Use it only to understand dose math; capsule-grade material is not sterile or validated for injection.
Is Ventfort FDA approved?expand_more
No. Ventfort is not approved by the FDA or EMA as a drug for any indication. In the United States it is sold only as a dietary supplement, meaning its claims have not been evaluated by the FDA and it is not intended to diagnose, treat, cure, or prevent any disease. It remains a research and educational compound whose efficacy data are largely limited to a single research group [6].
What is the half-life of Ventfort?expand_more
There is no established human half-life. Short di- to tetrapeptides are broken down by digestive and plasma enzymes within minutes, and oral absorption of the intact complex is unproven. The popular claim that one 30-day course 'lasts 4-6 months' is a manufacturer statement, not a measured pharmacokinetic value.
Can Ventfort be stacked with other Khavinson peptides?expand_more
In practice, Cytomax bioregulators are frequently cycled or combined (for example with Vesugen, the synthetic vascular tripeptide, or with other organ-specific complexes), and manufacturers market multi-peptide 'systems.' There is no controlled evidence on the safety or added benefit of stacking, so any combination is experimental. Discuss it with a qualified clinician, especially if you take cardiovascular or anticoagulant medication.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing Ventfort, plus the universal dosing calculator.
Academic References & Study Citations
Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. doi:10.3390/molecules26227053. View Scientific Paper →
Khavinson V, Ilina A, Kraskovskaya N, Linkova N, Kolchina N, Mironova E, Erofeev A, Petukhov M. Neuroprotective Effects of Tripeptides—Epigenetic Regulators in a Mouse Model of Alzheimer's Disease. Pharmaceuticals (Basel). 2021;14(6):515. doi:10.3390/ph14060515. View Scientific Paper →
Khavinson VKh. Peptides and Ageing. Neuro Endocrinol Lett. 2002;23 Suppl 3:11-144. PMID 12374906. View Scientific Paper →
Anisimov VN, Khavinson VKh. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. doi:10.1007/s10522-009-9249-8. View Scientific Paper →
Kitachev KV, Sazonov AB, Kozlov KL, Petrov KIu, Sliusarev AS, Khavinson VKh. [The efficacy of peptide bioregulators of vessels in lower limbs chronic arterial insufficiency treatment in old and elderly people]. Adv Gerontol. 2014;27(1):156-159. PMID 25051774. View Scientific Paper →
U.S. Food and Drug Administration. Dietary Supplements: regulatory status, labeling, and the 'not evaluated by the FDA' disclaimer. View Scientific Paper →